Select Publications
Journal articles
2024, 'A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: a registry based study', The Lancet Regional Health - Western Pacific, 53, http://dx.doi.org/10.1016/j.lanwpc.2024.101237
,2024, '‘High hopes for treatment’: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases', Health Expectations, 27, http://dx.doi.org/10.1111/hex.14063
,2024, 'Newborn screening for Duchenne muscular dystrophy: the perspectives of stakeholders', The Lancet Regional Health - Western Pacific, 45, http://dx.doi.org/10.1016/j.lanwpc.2024.101049
,2024, '‘Integrating Ethics and Equity with Economics and Effectiveness for newborn screening in the genomic age: A qualitative study protocol of stakeholder perspectives', PLoS ONE, 19, pp. 1 - 13, http://dx.doi.org/10.1371/journal.pone.0299336
,2024, 'Deciphering spinal muscular atrophy: the need for more research', The Lancet Neurology, 23, pp. 134 - 136, http://dx.doi.org/10.1016/S1474-4422(23)00502-1
,2023, 'Characterizing Common Phenotypes Across the Childhood Dementia Disorders: A Cross-sectional Study From Two Australian Centers', Pediatric Neurology, 149, pp. 75 - 83, http://dx.doi.org/10.1016/j.pediatrneurol.2023.09.006
,2023, 'Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective', Molecular and Cellular Pediatrics, 10, http://dx.doi.org/10.1186/s40348-023-00171-5
,2023, 'The Australian landscape of newborn screening in the genomics era', Rare Disease and Orphan Drugs Journal, 2, http://dx.doi.org/10.20517/rdodj.2023.30
,2023, 'Presymptomatic spinal muscular atrophy: a cautionary approach to the proposed new terminology', Brain, 146, pp. E65 - E66, http://dx.doi.org/10.1093/brain/awad061
,2023, 'The Carrier Frequency of Two SMN1 Genes in Parents of Symptomatic Children with SMA and the Significance of SMN1 Exon 8 in Carriers', Genes, 14, http://dx.doi.org/10.3390/genes14071403
,2023, 'Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study', The Lancet Child and Adolescent Health, 7, pp. 159 - 170, http://dx.doi.org/10.1016/S2352-4642(22)00342-X
,2023, 'Understanding the ongoing learning needs of Australian paediatricians: Evaluation of a pilot paediatric video teaching programme', Journal of Paediatrics and Child Health, 59, pp. 307 - 318, http://dx.doi.org/10.1111/jpc.16291
,2023, 'Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective', Expert Review of Neurotherapeutics, 23, pp. 571 - 586, http://dx.doi.org/10.1080/14737175.2023.2218549
,2023, 'Identification of Novel CSF-Derived miRNAs in Treated Paediatric Onset Spinal Muscular Atrophy: An Exploratory Study', Pharmaceutics, 15, http://dx.doi.org/10.3390/pharmaceutics15010170
,2023, 'Newborn Screening for the Diagnosis and Treatment of Duchenne Muscular Dystrophy', Journal of Neuromuscular Diseases, 10, pp. 15 - 28, http://dx.doi.org/10.3233/JND-221535
,2022, '‘Advocacy groups are the connectors’: Experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics', Health Expectations, 25, pp. 3175 - 3191, http://dx.doi.org/10.1111/hex.13625
,2022, 'Incidence of Duchenne muscular dystrophy in the modern era; an Australian study', European Journal of Human Genetics, 30, pp. 1398 - 1404, http://dx.doi.org/10.1038/s41431-022-01138-2
,2022, 'Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme', Developmental Medicine and Child Neurology, 64, pp. 625 - 632, http://dx.doi.org/10.1111/dmcn.15117
,2022, 'Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy', Annals of Clinical and Translational Neurology, 9, pp. 339 - 350, http://dx.doi.org/10.1002/acn3.51519
,2022, 'Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen', Journal of Physiology, 600, pp. 95 - 109, http://dx.doi.org/10.1113/JP282249
,2022, 'WE-149. Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen', Clinical Neurophysiology, 141, pp. S73 - S74, http://dx.doi.org/10.1016/j.clinph.2022.07.193
,2021, 'Spinal muscular atrophy: A new treatment paradigm of proactive care', Medicine Today, 22, pp. 55 - 60
,2021, '“We needed this”: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy', EClinicalMedicine, 33, pp. 100742, http://dx.doi.org/10.1016/j.eclinm.2021.100742
,2021, 'Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen', Journal of Neurology, Neurosurgery and Psychiatry, 92, pp. 78 - 85, http://dx.doi.org/10.1136/jnnp-2020-324254
,2020, 'Great expectations: Virus-mediated gene therapy in neurological disorders', Journal of Neurology, Neurosurgery and Psychiatry, 91, pp. 849 - 860, http://dx.doi.org/10.1136/jnnp-2019-322327
,2020, 'The implementation of newborn screening for spinal muscular atrophy: the Australian experience', Genetics in Medicine, 22, pp. 557 - 565, http://dx.doi.org/10.1038/s41436-019-0673-0
,2020, '7. Motor unit changes in children with spinal muscular atrophy treated with nusinersen', Clinical Neurophysiology, 131, pp. e3 - e4, http://dx.doi.org/10.1016/j.clinph.2019.11.040
,2019, 'Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy', Frontiers in Neurology, 10, pp. 898, http://dx.doi.org/10.3389/fneur.2019.00898
,2018, 'Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population', Archives of Disease in Childhood, 103, pp. 463 - 469, http://dx.doi.org/10.1136/archdischild-2017-313154
,2018, 'New and developing therapies in spinal muscular atrophy', Paediatric Respiratory Reviews, 28, pp. 3 - 10, http://dx.doi.org/10.1016/j.prrv.2018.03.003
,2018, 'DUCHENNE MUSCULAR DYSTROPHY - GENETICS', Neuromuscular Disorders, 28, pp. S97 - S98, http://dx.doi.org/10.1016/j.nmd.2018.06.264
,2015, 'Brain tumours in paediatrics: When should they be suspected?', Archives of Disease in Childhood, 100, pp. 1102 - 1103, http://dx.doi.org/10.1136/archdischild-2015-308729
,Conference Papers
2019, 'Genetic carrier screening for duchenne muscular dystrophy: the outcome of over twenty years of genetic counselling on disease epidemiology in a single-centre cohort study in new south wales (NSW), australia', Sydney Australia, presented at Australian and New Zealand Association of Neurologists, Sydney Australia
,Conference Abstracts
2019, 'GENETIC CARRIER SCREENING FOR DUCHENNE MUSCULAR DYSTROPHY: THE OUTCOME OF OVER TWENTY YEARS OF GENETIC COUNSELLING ON DISEASE EPIDEMIOLOGY IN A SINGLE-CENTRE COHORT STUDY IN NEW SOUTH WALES (NSW), AUSTRALIA', in JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, BMJ PUBLISHING GROUP, AUSTRALIA, Sydney, Vol. 90, presented at Annual Scientific Meeting of the Australian-and-New Zealand-Association-of-Neurologists (ANZAN), AUSTRALIA, Sydney, 21 May 2019 - 24 May 2019, http://dx.doi.org/10.1136/jnnp-2019-anzan.22
,Preprints
2024, Genetic newborn screening stakeholder perspectives, http://dx.doi.org/10.1101/2024.02.11.24302654
,<i>'We Needed This'</i>: Perspectives of Parents and Healthcare Professionals Involved in a Pilot Newborn Screening Program for Spinal Muscular Atrophy, http://dx.doi.org/10.2139/ssrn.3682109
,Integrating a Pilot Newborn Screening for Spinal Muscular Atrophy Into the Australian Public Healthcare System, http://dx.doi.org/10.2139/ssrn.3814778
,